Godavari Biorefineries has reported net loss of Rs. 19.32 crore for the quarter ended June 2026 as against net loss of Rs. 16.02 crore during the previous quarter ended June 2025. Meanwhile, total income rose to Rs. 559.9 crore in the quarter ended June 2026 as against Rs 534 crore during the previous quarter ended June 2025.

Commenting on the Results, Samir Somaiya, CMD said, “Q1 FY27 marked an important quarter in strengthening Godavari Biorefineries' integrated platform through strategic execution and operational milestones. During the quarter, we successfully commissioned our 200 KLPD grain-based distillery at Sameerwadi, increasing our total ethanol capacity to 800 KLPD and significantly enhancing our feedstock flexibility. This investment strengthens our ability to optimize operations across varying market conditions while creating a more resilient and future-ready ethanol business.

Our Bio-based Chemicals business delivered another strong quarter, with robust revenue growth, healthy margin expansion and improved profitability, reflecting the benefits of our debottlenecking initiatives and continued focus on higher-value specialty products. During the quarter, we also secured an Indian patent for a cost-effective process to manufacture branched alcohols, reflecting our continued focus on developing efficient and differentiated technologies.

Further advancing our innovation pipeline, we filed with the CDSCO to initiate preliminary efficacy trials for our lead anti-cancer molecule targeting Triple Negative Breast Cancer, with trials expected to commence from Q3 FY27, subject to regulatory approvals. This marks a significant milestone in translating our R&D efforts into potential clinical applications.

As we look ahead, our strategic priorities remain centered on expanding our high-value Bio-based Chemicals portfolio, strengthening strategic partnerships and commercialising innovation-led products. We are equally focused on enhancing ethanol fungibility to capitalise on India's evolving biofuel landscape, alongside sustained efforts in R&D and product innovation. These initiatives, supported by our integrated bio-refinery platform, position us well to deliver sustainable long-term growth and value creation.”